Two out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading down 88 points (-0.5%) at 17,785 as of Tuesday, May 31, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,627 issues advancing vs. 1,333 declining with 171 unchanged.

The Drugs industry currently sits up 2.0% versus the S&P 500, which is down 0.2%. Top gainers within the industry include

Celator Pharmaceuticals

(

CPXX

), up 70.9%,

Neurocrine Biosciences

(

NBIX

), up 8.1%,

Alnylam Pharmaceuticals

(

ALNY

), up 7.2%,

Grifols

(

GRFS

), up 2.8% and

Novo Nordisk A/S

(

NVO

), up 1.1%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Celgene

(

CELG

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Celgene is up $0.62 (0.6%) to $107.04 on light volume. Thus far, 1.4 million shares of Celgene exchanged hands as compared to its average daily volume of 4.7 million shares. The stock has ranged in price between $106.40-$107.44 after having opened the day at $107.25 as compared to the previous trading day's close of $106.43.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. Celgene has a market cap of $82.4 billion and is part of the health care sector. Shares are down 11.1% year-to-date as of the close of trading on Friday. Currently there are 14 analysts who rate Celgene a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Celgene

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, good cash flow from operations, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Celgene Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Gilead

(

GILD

) is up $1.08 (1.3%) to $86.90 on average volume. Thus far, 4.6 million shares of Gilead exchanged hands as compared to its average daily volume of 10.7 million shares. The stock has ranged in price between $86.05-$87.22 after having opened the day at $86.40 as compared to the previous trading day's close of $85.82.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $114.3 billion and is part of the health care sector. Shares are down 15.2% year-to-date as of the close of trading on Friday. Currently there are 11 analysts who rate Gilead a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Gilead

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, attractive valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Gilead Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Allergan

(

AGN

) is up $1.80 (0.8%) to $237.74 on heavy volume. Thus far, 4.6 million shares of Allergan exchanged hands as compared to its average daily volume of 5.1 million shares. The stock has ranged in price between $237.17-$242.35 after having opened the day at $241.99 as compared to the previous trading day's close of $235.94.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. Allergan has a market cap of $93.3 billion and is part of the health care sector. Shares are down 24.5% year-to-date as of the close of trading on Friday. Currently there are 12 analysts who rate Allergan a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Allergan

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full

Allergan Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).